On May 12, 2025, CytomX Therapeutics reported positive interim results from its Phase 1 study of CX-2051 for advanced colorectal cancer, showing a 28% overall response rate among 18 evaluable patients and a 94% disease control rate; as of March 31, 2025, the company had approximately $79.9 million in cash to support operations through mid-2026.